How reliable is the Signatera test?

Studies of patients followed up by the Signatera test have been published in the best-known international journals with respect to the most common solid tumours (colon, breast, lung) and the hard-to-diagnose bladder tumour. [2-5].

The Signatera test can also detect extremely low concentrations of circulating tumour DNA long before cancer recurrence can be seen by traditional imaging tools (e.g., X-ray, CT scans, and MRI).

Signatera is an entirely unique test thanks to its ability to accurately identify molecular residual tumours (MRT).

The Signatera test is highly sensitive and specific, meaning that if your test result is positive, there is a high likelihood that your cancer may recur without further treatment.

Signatera clinical study results

2. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.

3. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019. doi:10.1001/ jamaoncol. 2019.05282. [Epub ahead of print]

4. Christensen E, Birkenskamp-Demtroder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic ecacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019. doi: 10.1200/JCO.18.02052. [Epub ahead of print]

5. Coombes RC, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019. doi:10.1158/1078-0432.CCR-18-3663. [Epub ahead of print]

Please enter your personal details and send us your questions, and our experts will be happy to answer within 24 - 48 hours.

Thank your for your message. We will contact you in 24-48 hours.
Error. Please try again.